首页> 外文期刊>Allergy, Asthma & Immunology Research >Effectiveness of Same Versus Mixed Asthma Inhaler Devices: A Retrospective Observational Study in Primary Care
【24h】

Effectiveness of Same Versus Mixed Asthma Inhaler Devices: A Retrospective Observational Study in Primary Care

机译:相同版本的混合哮喘吸入器的有效性:初级保健中的回顾性观察研究。

获取原文
获取外文期刊封面目录资料

摘要

Purpose Correct use of inhaler devices is fundamental to effective asthma management but represents an important challenge for patients. The correct inhalation manoeuvre differs markedly for different inhaler types. The objective of this study was to compare outcomes for patients prescribed the same inhaler device versus mixed device types for asthma controller and reliever therapy. Methods This retrospective observational study identified patients with asthma (ages 4-80 years) in a large primary care database who were prescribed an inhaled corticosteroid (ICS) for the first time. We compared outcomes for patients prescribed the same breath-actuated inhaler (BAI) for ICS controller and salbutamol reliever versus mixed devices (BAI for controller and pressurised metered-dose inhaler [pMDI] for reliever). The 2-year study included 1 baseline year before the ICS prescription (to identify and correct for confounding factors) and 1 outcome year. Endpoints were asthma control (defined as no hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and severe exacerbations (hospitalisation or oral corticosteroids for asthma). Results Patients prescribed the same device (n=3,428) were significantly more likely to achieve asthma control (adjusted odds ratio, 1.15; 95% confidence interval [CI], 1.02-1.28) and recorded significantly lower severe exacerbation rates (adjusted rate ratio, 0.79; 95% CI, 0.68-0.93) than those prescribed mixed devices (n=5,452). Conclusions These findings suggest that, when possible, the same device should be prescribed for both ICS and reliever therapy when patients are initiating ICS.
机译:目的正确使用吸入器设备是有效控制哮喘的基础,但对患者而言是一项重要挑战。对于不同的吸入器类型,正确的吸入动作明显不同。这项研究的目的是比较使用相同的吸入器设备和混合类型的哮喘控制者和缓解剂治疗的患者的结局。方法这项回顾性观察性研究在大型初级保健数据库中确定了哮喘患者(4至80岁),这些患者首次开具了吸入性糖皮质激素(ICS)处方。我们比较了为ICS控制器和沙丁胺醇缓释药处方使用相同呼吸致动吸入器(BAI)的患者与混合器械(控制器为BAI处方使用缓释计量吸入器[pMDI]的患者)的结果。这项为期2年的研究包括ICS处方前的1个基准年(以识别和纠正混杂因素)和1个结局年。终点为哮喘控制(定义为无哮喘住院治疗,口服皮质类固醇或下呼吸道感染的抗生素)和严重加重(住院治疗或哮喘患者口服皮质类固醇)。结果开具相同装置(n = 3,428)的患者更容易实现哮喘控制(调整后的优势比,1.15; 95%置信区间[CI],1.02-1.28),记录的严重急性发作率明显降低(调整后的比例, 0.79; 95%CI,0.68-0.93)比那些规定的混合设备(n = 5,452)。结论这些发现表明,在可能的情况下,当患者开始ICS时,应为ICS和缓解药物处方相同的设备。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号